JP2017519807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519807A5 JP2017519807A5 JP2017501186A JP2017501186A JP2017519807A5 JP 2017519807 A5 JP2017519807 A5 JP 2017519807A5 JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017519807 A5 JP2017519807 A5 JP 2017519807A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dose
- patient
- disease
- blood concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 230000016396 cytokine production Effects 0.000 claims description 9
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 230000007658 neurological function Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 230000036765 blood level Effects 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 206010033892 Paraplegia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000032930 Spastic paraplegia Diseases 0.000 claims description 2
- 208000034799 Tauopathies Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022586P | 2014-07-09 | 2014-07-09 | |
| US62/022,586 | 2014-07-09 | ||
| PCT/US2015/039539 WO2016007616A1 (en) | 2014-07-09 | 2015-07-08 | Methods for treating neurologic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519807A JP2017519807A (ja) | 2017-07-20 |
| JP2017519807A5 true JP2017519807A5 (OSRAM) | 2018-08-16 |
| JP6660369B2 JP6660369B2 (ja) | 2020-03-11 |
Family
ID=55064826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501186A Active JP6660369B2 (ja) | 2014-07-09 | 2015-07-08 | 神経障害を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9579322B2 (OSRAM) |
| EP (1) | EP3166610B1 (OSRAM) |
| JP (1) | JP6660369B2 (OSRAM) |
| CN (3) | CN113018300B (OSRAM) |
| WO (1) | WO2016007616A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113018300B (zh) | 2014-07-09 | 2025-11-25 | 爱普制药有限责任公司 | 用于治疗神经病症的方法 |
| WO2017075013A1 (en) | 2015-10-26 | 2017-05-04 | Eip Pharma, Llc | Methods and compositions for recovery from stroke |
| EP3445369A4 (en) | 2016-04-21 | 2020-03-04 | Eip Pharma, LLC | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA |
| WO2019056003A1 (en) | 2017-09-18 | 2019-03-21 | Eip Pharma, Llc | CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745) |
| CA3078232A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019178153A1 (en) * | 2018-03-12 | 2019-09-19 | Eip Pharma, Llc | Pharmaceutical formulations of neflamapimod |
| AU2019384074B2 (en) * | 2018-11-20 | 2025-04-10 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| AU2020295410A1 (en) * | 2019-06-18 | 2022-01-20 | Indivior Uk Limited | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
| AU2020296012A1 (en) | 2019-06-18 | 2022-01-20 | Indivior Uk Limited | Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist |
| CA3147271A1 (en) * | 2019-07-12 | 2021-01-21 | Eip Pharma, Inc. | Compositions and methods for treating dementia with lewy bodies |
| WO2022099095A1 (en) * | 2020-11-06 | 2022-05-12 | Eip Pharma, Inc. | Treatment of gait dysfunction in neurodegenerative disease |
| CN113616795B (zh) * | 2021-08-31 | 2023-06-20 | 上海交通大学医学院附属瑞金医院 | Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍 |
| US20240363225A1 (en) * | 2023-04-27 | 2024-10-31 | Remepy Health Ltd | Digital therapeutics for improved neuro-connectivity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| CN101103969A (zh) * | 2002-12-24 | 2008-01-16 | 神经化学（国际）有限公司 | 治疗β淀粉样蛋白相关疾病的治疗性制品 |
| US20050203111A1 (en) | 2004-03-12 | 2005-09-15 | Vvii Newco 2003, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| US20080044439A1 (en) | 2004-03-11 | 2008-02-21 | David Nathaniel E | Compositions and Methods for Preventing and Treating Skin and Hair Conditions |
| EP1948599A1 (en) | 2005-11-08 | 2008-07-30 | Ranbaxy Laboratories Limited | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| JP5432710B2 (ja) | 2006-06-23 | 2014-03-05 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | Ａβ及びシヌクレイン凝集の阻害剤 |
| US8304413B2 (en) * | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| RU2013149800A (ru) * | 2011-04-08 | 2015-05-20 | Афраксис Холдингз, Инк. | 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака |
| EP2707369B1 (en) * | 2011-05-09 | 2016-07-27 | Eip Pharma, LLC | Compositions and methods for treating alzheimer's disease |
| CN113018300B (zh) | 2014-07-09 | 2025-11-25 | 爱普制药有限责任公司 | 用于治疗神经病症的方法 |
-
2015
- 2015-07-08 CN CN202110348688.2A patent/CN113018300B/zh active Active
- 2015-07-08 CN CN201580037336.8A patent/CN106659723A/zh active Pending
- 2015-07-08 US US14/794,469 patent/US9579322B2/en active Active
- 2015-07-08 JP JP2017501186A patent/JP6660369B2/ja active Active
- 2015-07-08 EP EP15819113.0A patent/EP3166610B1/en active Active
- 2015-07-08 CN CN202110783304.XA patent/CN114010641A/zh active Pending
- 2015-07-08 WO PCT/US2015/039539 patent/WO2016007616A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519807A5 (OSRAM) | ||
| Hucklenbroich et al. | Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo | |
| JP2016199576A5 (OSRAM) | ||
| NO20091888L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| EA201992178A1 (ru) | Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| Khatoon et al. | The role of natural products in Alzheimer's and Parkinson's disease | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| Sartorius et al. | Medial Forebrain Bundle Stimulation—Speed Access to an Old or Entry into a New Depression Neurocircuit? | |
| JP7062804B2 (ja) | レビー小体病の治療および／または予防剤 | |
| RU2325146C1 (ru) | Способ реабилитации больных рассеянным склерозом с нарушениями двигательных функций | |
| Nomoto et al. | Clinical nonmotor aspect of A2A antagonist in PD treatment | |
| Deleyrolle et al. | Cilia at the crossroads of tumor treating fields and chemotherapy | |
| Faraz et al. | Effect of Hypothyroidism on Motor Nerve Conduction Studies: A Cross Sectional Study | |
| JP6869893B2 (ja) | 前頭葉機能障害治療剤 | |
| JP2015137243A (ja) | 脳内アミノ酸量の調整剤 | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| Farrell | Clinical commentary on “De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine”. |